Tardy development of safe medicines for children: a Nordic network offers new platform to reduce this inequity

This is the authors' abstract. We don't add key points for this paper.

Less than thirty percent of all marketed drugs worldwide have a paediatric licensing, and less than fifty percent of all marketed drugs are registered for children; in neonates less than ten percent (1, 2). This is not a fair situation since children should have the same right and access to tested medicines as adults. Even so, we see that off-label drugs are increasingly prescribed to children of all ages. This article is protected by copyright. All rights reserved.